CD19 and non-Hodgkin lymphoma: CD19 CAR-T cells are engineered to recognize CD19-expressing B cell malignancies and two CAR-T products are FDA approved for the treatment of relapsed/refractory patients with non-Hodgkin lymphoma (NHL) (1).